Pulmonary Vascular Disease News

The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.

Following 15-minute use of an electronic nicotine delivery system, or ENDS, lung function fell and blood pressure and heart rate rose in long-term users vs. nonusers, according to results published in CHEST.

Janus kinase inhibitor therapy in short durations did not significantly increase the risk for major adverse cardiovascular events or venous thromboembolism in patients with low cardiovascular risk profiles, according to a study.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

The FDA did not meet its Prescription Drug User Fee Act goal date that would extend Yutrepia as a treatment for patients with pulmonary hypertension associated with interstitial lung disease, according to a press release.

Children who had a thromboembolic pulmonary embolism rarely developed post-PE syndrome, including high blood pressure in the lungs or cardiac or functional impairment, according to a study published in Blood.

The subset of patients with high-risk pulmonary embolism who had hemodynamic collapse had an in-hospital mortality rate of 42%, according to a retrospective analysis of a large registry.

When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review.

Male patients, Black patients and rural area residents with pulmonary embolism had poorer age-adjusted mortality rates than their respective opposing demographics, according to results published in Annals of the American Thoracic Society.